EUVIMEDEUVIMED entdecken
Systematische ÜbersichtUmbrella ReviewOpen Access · CC BY-NC 4.0

Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews

Giancarlo De la Torre Canales, Mariana Barbosa Câmara-Souza, Malin Ernberg, Essam Ahmed Al-Moraissi, Anastasios Grigoriadis, Rodrigo Lorenzi Poluha, Maria Christidis, Hajer Jasim, Anna Lövgren, Nikolaos Christidis

Drugs · 2024-07 · 84 (7) · 779-809

DOI: 10.1007/s40265-024-02048-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Drugs, online erschienen am 20.06.2024. Verfasst von Giancarlo De la Torre Canales und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oral Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Box 4064, SE-14104, Huddinge, Sweden. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Temporomandibular Joint Disorders, Systematic Reviews as Topic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Temporomandibular disorders (TMDs) encompass several conditions that cause pain and impair function of the masticatory muscles (M-TMDs) and temporomandibular joints. There is a large interest among clinicians and researchers in the use of botulinum toxin-A (BoNT-A) as a treatment for M-TMD. However, due to the lack of consistent evidence regarding the efficacy as well as adverse events of BoNT-A, clinical decision making is challenging. Therefore, this umbrella review aimed to systematically assess systematic reviews (SRs) evaluating BoNT-A treatment effects on pain intensity, mandibular movements, and adverse events in patients with M-TMDs. METHOD: An electronic search was undertaken in the databases MEDLINE, EMBASE, CINAHL, Cochrane Central Registry of Controlled Trials (CENTRAL), Web of Science, Epistemonikos, ClinicalTrials.gov, and ICTRP to identify SRs investigating BoNT-A effects on M-TMDs, published from the inception of each database until 6 December 2023. The quality of evidence was rated according to the critical appraisal checklist developed by the umbrella review methodology working group. Only high-quality SRs were included. RESULTS: In total, 18 SRs were included. BoNT-A was shown to be more effective than placebo to reduce pain intensity, but not compared to standard treatments. Additionally, BoNT-A was not superior to placebo or standard treatments regarding improvement of mandibular movements. BoNT-A was considered to have a higher risk for adverse events on muscle and bony tissue compared with other treatments. CONCLUSION: The synthesis in this umbrella review provides the highest level of evidence present. Taken together, there are indications of effectiveness of BoNT-A for treatment of M-TMDs, supported by moderate evidence. However, considering the risk of causing serious adverse events, treatment with BoNT-A is recommended to be the last treatment alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ATemporomandibular Joint DisordersSystematic Reviews as TopicHumansMasticatory MusclesNeuromuscular Agents

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Division of Oral Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Box 4064, SE-14104, Huddinge, Sweden.
  • Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Almada, Portugal.
  • Department of Dentistry, Ingá University Center, Uningá, Paraná, Brazil.
  • Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Thamar University, Thamar, Yemen.
  • Department of Dentistry, State University of Maringa, Paraná, Brazil.
  • The Institute of Health Sciences, The Swedish Red Cross University, SE-141 21, Huddinge, Sweden.

Förderung

  • Karolinska Institute

Zitieren

APA

De la Torre Canales, G., Câmara-Souza, M. B., Ernberg, M., Al-Moraissi, E. A., Grigoriadis, A., Poluha, R. L., Christidis, M., Jasim, H., Lövgren, A., & Christidis, N. (2024). Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews. Drugs, 84(7), 779-809. https://doi.org/10.1007/s40265-024-02048-x

Vancouver

De la Torre Canales G, Câmara-Souza MB, Ernberg M, Al-Moraissi EA, Grigoriadis A, Poluha RL, et al. Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews. Drugs. 2024;84(7):779-809. doi:10.1007/s40265-024-02048-x

BibTeX
@article{DelaTorreCanales2024,
  author = {De la Torre Canales, Giancarlo and Câmara-Souza, Mariana Barbosa and Ernberg, Malin and Al-Moraissi, Essam Ahmed and Grigoriadis, Anastasios and Poluha, Rodrigo Lorenzi and Christidis, Maria and Jasim, Hajer and Lövgren, Anna and Christidis, Nikolaos},
  title = {Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews},
  journal = {Drugs},
  year = {2024},
  volume = {84},
  number = {7},
  pages = {779--809},
  doi = {10.1007/s40265-024-02048-x}
}
Kostenlos starten →